FRANKFURT (Reuters) – Bayer’s adjusted core earnings rose 15.8 percent in the fourth quarter, boosted by the addition of U.S. seeds maker Monsanto (NYSE:) and as its consumer healthcare business bounced back from earlier declines.
Fourth-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.07 billion euros (1.78 billion pounds), the maker of pharmaceuticals and farming pesticides said on Wednesday, beating the average analyst projection of 2.0 billion euros.
Previously announced write-downs on the value of consumer health brands and one-off charges from the closure of a German haemophilia drug plant led to a quarterly net loss of 3.9 billion euros.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.